Netherland has observed a rise in the prevalence of type 2 diabetes during the last decade. As the Dutch population is ageing and the incidence of obesity is a significant risk factor for diabetes is increasing, survival is improving, and multiple screening initiatives are implemented in the Netherlands. In 2013, nearly half the Dutch population suffered from at least one chronic disorder. One of the disorders with a high disease burden and reduction in quality of life is diabetes mellitus. Netherlands Diabetes Market is gardened to reach USD 4.48 Billion by the year 2025.
In the Netherlands, the prevalence of diabetes mellitus (DM) is increasing rapidly. Netherlands care for diabetes is mainly concentrated in primary health care, with responsibility for most aspects of care in the hands of general practitioners. In general, primary health care in The Netherlands provides a good standard of care for subjects with DM. Another point of concern is the rise in the prevalence of obesity, leading to a vast increase in subjects with metabolic syndrome. DM (diabetes mellitus) care and its provision will continue to play an important role in health care in The Netherlands.
The market of Continuous Glucose Monitoring (CGM) Device, Self Monitoring Blood Glucose Device, Insulin Pen and Insulin Pump are growing due to the rising awareness for diabetes in Netherland. Diabetes care in The Netherlands has reached a high level of quality, but there is still an opportunity for further improvement. Not only is it a medical challenge but at least as much a burden for the Dutch economy and society. To fight with these risk factors, the Netherlands rolled out national health programs. In 2018, The National Prevention Agreement which was approved and it sets out ambitious goals to make the Netherlands healthier by 2040, but it was in March 2019 that they are still far from reach.
Follow the Link for Report Customization: https://www.renub.com/netherlands-diabetes-market-p.php
Over the past decade, the National Action program Diabetes (NAD) was implemented in the Netherlands. It is aimed to introduce the Care Standard (CS) for diabetes using a specific implementation plan and to pilot in several regions. In the year December 2019, Roche received CE Mark for its Accu-Chek SugarView app. Accu-Chek SugarView is the first app that checks the blood glucose ranges by taking pictures with the Smartphone camera without the requirement for a blood glucose meter.
Renub Research report titled “Netherlamds Diabetes Market & Forecast, By Continuous Glucose Monitoring (CGM Market by Components, Glucose Sensor, Transmitter, CGM User, Reimbursement), Self Monitoring Blood Glucose Device Analysis (SMBG Market by, Test Strips, Lancet, Meter, Blood Glucose Device Users & Reimbursement) Insulin Pen Analysis – (User, Types – Disposable, Reusable and Smart Insulin Pen, Insulin Pen Needle Market, Reimbursement Policies), Insulin Pump Analysis- (Users, Market & Differentiation Points of Insulin Pump Products, Training Model for Patients & HCP, Reimbursement Policies) Companies (B. Braun Melsungen AG, Eli Lilly and Company, Artsana S.p.A, BD, Novo Nordisk A/S, Owen Mumford Ltd, Ypsomed AG, Medtronic, Insulet Corporation, LifeScan Inc., Abbott Laboratories, Dexcom Inc and Roche)” provides a complete analysis of Netherland Insulin Delivery Devices Market.
Request a free Sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=netherlands-diabetes-market-p.php
Segments Market based on Devices
1. Continuous Glucose Monitoring (CGM)
2. Self Monitoring Blood Glucose (SMBG)
3. Insulin Pen
4. Insulin Pump
Netherlands Diabetes Sub-Segment Analysis
1. Continuous Glucose Monitoring (CGM)
1.1. Glucose Sensor Market & Forecast
1.2. CGM Transmitter Market & Forecast
1.3. CGM User
1.4. CGM Reimbursement
2.1. Test Strips Market and Forecast
2.2. Lancet Market and Forecast
2.3. Meter Market and Forecast
2.4. Blood Glucose (SMBG) Users
2.5. Blood Glucose Devices Reimbursement
3. Insulin Pen Market
3.1. Disposable Insulin Pen
3.2. Reusable Insulin Pen
3.3. Smart Insulin Pen
3.4. Insulin Pen Needle Market
3.5. Insulin Pen Users
3.6. Reimbursement Policies
4. Insulin Pump Market
4.1. Insulin Pump Market
4.2. Insulin Pump Users
4.3. Insulin Pump Products
4.4. Reimbursement Policies
All the 14 Companies Studied in the Report have been Studied from 3 Points
• Company Overview
• Recent Developments
• Financial Insight
1. B. Braun Melsungen AG
2. Eli Lilly and Company
3. Artsana S.p.A
5. Novo Nordisk A/S
6. Owen Mumford Ltd
7. Ypsomed AG
9. Insulet Corporation
10. LifeScan Inc.
11. Abbott Laboratories
13. Dexcom Inc
Key Benefits of the Report
• This report provides current market estimates and forecasts for the Netherland Diabetic Market.
• Detailed analysis of the key market segments such as source, geography and applications; provides a comprehensive understanding of the market.
• Netherland Diabetic Market – Growth Drivers and Challenges.
• Key sustainability strategies adopted by market players.
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises of major players in Life Sciences, Information Technology, Telecom, Financial Services (Banking, Insurance), Energy, Retail, Manufacturing, Automotive, and Social sector. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.
Phone No: +1 678-302-0700 (USA) | +91-120-421-9822 (IND)
Email: [email protected]
Follow on Linkedin: https://www.linkedin.com/company/renub-research